Risperidone

Generic Name: Risperidone

Brand Names: Perseris, Risperdal, Rykindo, Uzedy, Okedi

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇FN_₄O_₂

CAS Number: 106266-06-2

Unique Ingredient Identifier: L6UH7ZF8HC

Background: Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...

Indication: Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...

Associated Conditions: Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease

Phase 3

Completed

Conditions: Dementia
Alzheimer Disease
Mental Disorders

First Posted Date: 2002-05-03

Last Posted Date: 2011-02-01

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 473

Registration Number: NCT00034762

A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.

Phase 3

Completed

Conditions: Schizophrenia
Psychotic Disorders

First Posted Date: 2002-05-03

Last Posted Date: 2011-01-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 141

Registration Number: NCT00034775

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2002-05-01

Last Posted Date: 2006-07-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 326

Registration Number: NCT00034580

Specific Interventions for Agitation in Alzheimer's Disease

Not Applicable

Completed

Conditions: Dementia
Alzheimer's Disease

First Posted Date: 2001-07-05

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00018291

Locations: 🇺🇸
Palo Alto VA Health Care System, Menlo Park, California, United States

Antipsychotic Response in Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2001-07-05

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00018668

Locations: 🇺🇸
Department of Veterans Affairs, San Diego, California, United States

CATIE-Alzheimer's Disease Trial

Not Applicable

Completed

Conditions: Alzheimer's Disease

First Posted Date: 2001-04-23

Last Posted Date: 2015-06-17

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 450

Registration Number: NCT00015548

Locations: 🇺🇸
VA Medical Center, Coatesville, Pennsylvania, United States
🇺🇸
University of California, Irvine Medical Center, Irvine, California, United States
🇺🇸
Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States

and more 31 locations

CATIE- Schizophrenia Trial

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2001-04-09

Last Posted Date: 2015-06-17

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 1600

Registration Number: NCT00014001

Locations: 🇺🇸
Staten Island University Hospital, Staten Island, New York, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Northwestern Medical School Department of Psychiatry, Chicago, Illinois, United States

and more 51 locations

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

Not Applicable

Completed

Conditions: Bipolar Disorder

First Posted Date: 2001-03-15

Last Posted Date: 2007-05-04

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 5000

Registration Number: NCT00012558

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 8 locations

Glucose Regulation During Risperidone and Olanzapine Treatment

Not Applicable

Conditions: Schizophrenia

First Posted Date: 2000-09-08

Last Posted Date: 2006-10-12

Lead Sponsor: National Center for Research Resources (NCRR)

Registration Number: NCT00006195

Locations: 🇺🇸
Washington University, St. Louis, Missouri, United States

Treatment of Autism in Children and Adolescents

Phase 3

Completed

Conditions: Autistic Disorder

First Posted Date: 2000-04-03

Last Posted Date: 2014-04-17

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 101

Registration Number: NCT00005014

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Yale Univ, New Haven, Connecticut, United States
🇺🇸
Indiana Univ / Riley Hosp for Children, Indianapolis, Indiana, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy